

San Diego, California; DFO Partnership, San Francisco, California; First Franklin Financial Corporation, San Jose, California; First Franklin Funding Corporation, San Jose, California; General Fidelity Life Insurance Company, San Diego, California; Security Pacific Capital Leasing Corporation, San Francisco, California; and Security Pacific Housing Services, Inc., San Diego, California. The nonbanking activities of the companies to be acquired also are listed in the notice and include extending credit and servicing loans, pursuant to 12 CFR 225.28(b)(1); leasing personal and real property, pursuant to 12 CFR 225.28(b)(3); operating a savings association through Bank of America, FSB, Portland, Oregon, pursuant to 12 CFR 225.28(b)(4)(ii); providing financial and investment advisory services, pursuant to 12 CFR 225.28(b)(6); providing securities brokerage, riskless principal, private placement, futures commission merchant, and other agency transactional services, pursuant to 12 CFR 225.28(b)(7); underwriting and dealing in certain government obligations and money market instruments that state member banks may underwrite or deal in, pursuant to 12 CFR 225.28(b)(8)(i); acting as principal, agent, or broker in connection with the sale of credit-related insurance, pursuant to 12 CFR 225.28(b)(11)(i); engaging in community development activities, pursuant to 12 CFR 225.28(b)(12); providing data processing and data transmission services, pursuant to 12 CFR 225.28(b)(14); and engaging in all activities that BankAmerica currently is authorized by Board Order to conduct. As part of the proposed transaction, NationsBank proposes to engage through BancAmerica Robertson Stephens, San Francisco, California, in underwriting and dealing in all types of debt and equity securities (other than interests in open-end investment companies) to a limited extent in accordance with previous Board decisions. In addition, NationsBank proposes to engage, directly or indirectly through its subsidiaries, in certain other activities that the Board previously has approved by Order, including providing administrative services to open-end and closed-end investment companies.

In connection with the proposed transaction, NationsBank also has applied to acquire an option to purchase up to 19.9 percent of the outstanding shares of BankAmerica's common stock. BankAmerica also has applied to acquire an option to purchase up to 19.9 percent of the outstanding shares of

NationsBank Corporation's common stock. These options would expire upon consummation of the merger. Comments regarding this application must be received not later than June 24, 1998.

**B. Federal Reserve Bank of Chicago** (Philip Jackson, Applications Officer) 230 South LaSalle Street, Chicago, Illinois 60690-1413:

1. *Associated Banc-Corp*, Green Bay, Wisconsin; to merge with Citizens Bankshares, Inc., Shawano, Wisconsin, and thereby indirectly acquire Citizens Bank, National Association, Shawano, Wisconsin.

In connection with this application, Applicant also has applied to acquire Wisconsin Finance Corporation, Shawano, Wisconsin, and thereby indirectly acquire Citizens Financial Services, Inc., Shawano, Wisconsin, and thereby engage in extending credit and servicing loans and acting as principal, agent, or broker for credit related insurance, pursuant to §§ 225.28(b)(1) and 225.28(b)(11)(ii) of the Board's Regulation Y.

2. *West Burlington Bancorporation, Inc.*, West Burlington, Iowa; to become a bank holding company by acquiring 100 percent of the voting shares of West Burlington Bank, West Burlington, Iowa.

**C. Federal Reserve Bank of Minneapolis** (Karen L. Grandstrand, Vice President) 90 Hennepin Avenue, P.O. Box 291, Minneapolis, Minnesota 55480-0291:

1. *M.I.F. Limited*, Chisholm, Minnesota; to become a bank holding company by acquiring 100 percent of the voting shares of Chisholm Bancshares, Inc., Chisholm, Minnesota, and thereby indirectly acquire First National Bank, Chisholm, Minnesota.

2. *Norwest Corporation*, Minneapolis, Minnesota; to acquire 100 percent of the voting shares of First Bancshares, of Valley City, Inc., Valley City, North Dakota, and thereby indirectly acquire First State Bank of Casselton, Casselton, North Dakota; Litchville State Bank, Litchville, North Dakota; and First National Bank of Valley City, Valley City, North Dakota.

In connection with this application, Applicant also has applied to acquire Peoples Insurance Agency, Inc., Valley City, North Dakota, and thereby engage in general insurance agency activities, pursuant to § 225.28(b)(1)(vii) of the Board's Regulation Y.

3. *Norwest Corporation*, Minneapolis, Minnesota; to acquire 100 percent of the voting shares of Little Mountain Bancshares, Inc., Monticello, Minnesota, and thereby indirectly acquire First National Bank of Monticello, Monticello, Minnesota.

In connection with this application, Applicant proposes to transfer the mortgage origination and servicing business of the First National Bank of Monticello to its wholly owned subsidiary, Norwest Mortgage, Inc., Des Moines, Iowa. Norwest Mortgage Inc., proposes to engage in these activities, pursuant to § 225.28(b)(1) of the Board's Regulation Y.

**D. Federal Reserve Bank of San Francisco** (Maria Villanueva, Manager of Analytical Support, Consumer Regulation Group) 101 Market Street, San Francisco, California 94105-1579:

1. *UCBH Holdings, Inc.*, San Francisco, California; to become a bank holding company by acquiring 100 percent of the voting shares of United Commercial Bank, F.S.B., San Francisco, California. United Commercial Bank, F.S.B., will convert to a bank charter.

Board of Governors of the Federal Reserve System, May 19, 1998.

**Jennifer J. Johnson,**

*Deputy Secretary of the Board.*

[FR Doc. 98-13790 Filed 5-21-98; 8:45 am]

BILLING CODE 6210-01-F

## FEDERAL RESERVE SYSTEM

### Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y, (12 CFR Part 225) to engage *de novo*, or to acquire or control voting securities or assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated

or the offices of the Board of Governors not later than June 9, 1998.

#### A. Federal Reserve Bank of Philadelphia

(Michael E. Collins, Senior Vice President) 100 North 6th Street, Philadelphia, Pennsylvania 19105-1521:

1. *Commerce Bancorp*, Cherry Hill, Pennsylvania; to acquire Commerce Capital, Philadelphia, Pennsylvania, and thereby engage in Tier II securities underwriting and dealing and related activities, including bonds issued by not-for-profit entities that qualify under Section 501(c)(3) of the Internal Revenue Code for a tax exempt status; and bonds issued by private entities that qualify under Section 142(d) of the Internal Revenue Code for a partially tax exempt status (subject to only to the alternative minimum tax). See Citicorp, 75 Fed. Res. Bull., 751 (1989) & 83 Fed. Res. Bull. 510 (1997).

#### B. Federal Reserve Bank of Chicago

(Philip Jackson, Applications Officer) 230 South LaSalle Street, Chicago, Illinois 60690-1413:

1. *CITBA Financial Corporation*, Mooresville, Indiana; to acquire Independent Bankers Life Insurance Company of Indiana, Phoenix, Arizona, a reinsurance subsidiary, and thereby indirectly engage in underwriting credit life, accident and health insurance directly related to extensions of credit by the banks and bank holding companies owning stock in the insurance agency, pursuant to § 225.28(b)(11)(i) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, May 19, 1998.

**Jennifer J. Johnson,**

*Deputy Secretary of the Board.*

[FR Doc. 98-13788 Filed 5-21-98; 8:45 am]

BILLING CODE 6210-01-F

## FEDERAL RESERVE SYSTEM

### Sunshine Act Meeting

**AGENCY HOLDING THE MEETING:** Board of Governors of the Federal Reserve System.

**TIME AND DATE:** 10:00 a.m., Wednesday, May 27, 1998.

**PLACE:** Marriner S. Eccles Federal Reserve Board Building, 20th and C Streets, NW., Washington, DC 20551.

**STATUS:** Closed.

#### MATTERS TO BE CONSIDERED:

1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.
2. Any matters carried forward from a previously announced meeting.

**CONTACT PERSON FOR MORE INFORMATION:** Joseph R. Coyne, Assistant to the Board; 202-452-3204.

**SUPPLEMENTARY INFORMATION:** You may call 202-452-3206 beginning at approximately 5 p.m. two business days before the meeting for a recorded announcement of bank and bank holding company applications scheduled for the meeting; or you may contact the Board's Web site at <http://www.bog.frb.fed.us> for an electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.

**DATED:** May 20, 1998.

**Jennifer J. Johnson,**

*Deputy Secretary of the Board.*

[FR Doc. 98-13862 Filed 5-20-98; 12:55 pm]

BILLING CODE 6210-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 98P-0160]

#### Determination That Cimetidine 100 mg Tablets Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) has determined that cimetidine 100 milligram (mg) tablets were not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for drugs that refer to cimetidine 100 mg tablets.

**FOR FURTHER INFORMATION CONTACT:** Virginia G. Beakes, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2041.

**SUPPLEMENTARY INFORMATION:** In 1984, Congress enacted the Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98-417) (the 1984 amendments), which authorized the approval of duplicate versions of drug products approved under an ANDA procedure. ANDA sponsors must, with certain exceptions, show that the drug for which they are seeking approval contains the same active ingredient in the same strength and dosage form as the "listed drug," which is a version of the drug that was previously approved under a new drug

application (NDA). Sponsors of ANDA's do not have to repeat the extensive clinical testing otherwise necessary to gain approval of an NDA. The only clinical data required in an ANDA are data to show that the drug that is the subject of the ANDA is bioequivalent to the listed drug.

The 1984 amendments included what is now section 505(j)(6) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(6)), which requires FDA to publish a list of all approved drugs. FDA publishes this list as part of the "Approved Drug Products with Therapeutic Equivalence Evaluations," which is generally known as the "Orange Book." Under FDA's regulations, drugs are withdrawn from the list if the agency withdraws or suspends approval of the drug's NDA or ANDA for reasons of safety or effectiveness, or if FDA determines that the listed drug was withdrawn from sale for reasons of safety or effectiveness (21 CFR 314.162). Regulations also provide that the agency must make a determination as to whether a listed drug was withdrawn from sale for reasons of safety or effectiveness before an ANDA that refers to that listed drug may be approved (§ 314.161(a)(1) (21 CFR 314.161(a)(1))). FDA may not approve an ANDA that does not refer to a listed drug.

In citizen petitions dated March 9, 1998 (Docket No. 98P-0160/CP 1), and March 13, 1998 (Docket No. 98P-0160/CP 2), submitted in accordance with 21 CFR 314.122, Apotex Corp. and Novopharm Limited, respectively, requested that the agency determine whether cimetidine (Tagamet HB) 100 mg tablets were withdrawn from sale for reasons of safety or effectiveness. Cimetidine 100 mg tablets are the subject of approved NDA 20-238 held by SmithKline Beecham Consumer Healthcare LP (SmithKline Beecham). In 1997, SmithKline Beecham withdrew cimetidine 100 mg tablets from sale.

FDA has reviewed its records and, under § 314.161, has determined that cimetidine 100 mg tablets were not withdrawn from sale for reasons of safety or effectiveness. Accordingly, the agency will maintain cimetidine 100 mg tablets in the "Discontinued Drug Product List" section of the Orange Book. The "Discontinued Drug Product List" delineates, among other items, drug products that have been discontinued from marketing for reasons other than safety or effectiveness. ANDA's that refer to cimetidine 100 mg tablets may be approved by the agency.